Moderna said it would ask regulators to approve two small-dose shots, as the vaccine generated a similar immune response to adults in its clinical trial.
If authorised, Moderna's vaccine could be the first authorized shot for children under the age of 5 in the United States, and many parents of young children have been waiting on a vaccine.
The nation’s 18 million children under 5 are the only age group not yet eligible for vaccination. Competitor Pfizer currently offers kid-sized doses for school-age children and full-strength shots for those 12 and older. How effective is the Moderna vaccine? The Omicron variant of Covid-19 was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5-year-olds and 44% effective for children 6 months to under 2 years old.
It said these figures were consistent with the lower effectiveness against Omicron seen in adults who had received two doses of its vaccine.